A5075134017- Chemotherapy-induced cardiotoxicity and mitigation
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Cancer, Stress, Anesthesia, and Immune Response
- Cancer, Lipids, and Metabolism
- Metabolism, Diabetes, and Cancer
- Diabetes Treatment and Management
- Cardiac Imaging and Diagnostics
- Cardiac electrophysiology and arrhythmias
- Neuroendocrine Tumor Research Advances
- Radiopharmaceutical Chemistry and Applications
- Cancer, Hypoxia, and Metabolism
- Lipoproteins and Cardiovascular Health
- Chemotherapy-induced organ toxicity mitigation
- Venous Thromboembolism Diagnosis and Management
- Pulmonary Hypertension Research and Treatments
- Inflammatory mediators and NSAID effects
- Histone Deacetylase Inhibitors Research
- Pancreatic function and diabetes
- Heart Failure Treatment and Management
- COVID-19 and healthcare impacts
- Electron Spin Resonance Studies
- Synthesis and Biological Evaluation
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2016-2025
Ospedale Versilia
2021-2024
Tumori Foundation
2017-2024
Azienda Ospedaliera San Camillo-Forlanini
2023-2024
Ospedale Sacro Cuore Don Calabria
2024
University of Messina
2016-2023
Fondazione IRCCS Istituto Nazionale dei Tumori
2014-2023
Istituti di Ricovero e Cura a Carattere Scientifico
2021-2023
University of Naples Federico II
2021-2023
Istituto Nazionale di Fisica Nucleare, Sezione di Napoli
2023
Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter 2, reduced risk hospitalization for heart failure and cardiovascular death in type 2 diabetic patients EMPA-REG OUTCOME trial. Recent trials evidenced several cardio-renal benefits EMPA non-diabetic through involvement biochemical pathways that are still to be deeply analysed. We aimed evaluate effects on myocardial strain mice treated with doxorubicin (DOXO) analysis NLRP3 inflammasome MyD88-related resulting...
Doxorubicin is a highly active antineoplastic agent, but its clinical use limited because of cardiotoxicity. Although nutraceuticals endowed with anti-inflammatory properties exert cardioprotective activity, their bioavailability and stability are inconsistent. In an attempt to address this issue, we evaluated whether bioavailable nanoemulsions loaded (curcumin fresh dry tomato extracts rich in lycopene) protect cardiomyoblasts (H9C2 cells) from doxorubicin-induced toxicity. Nanoemulsions...
Abstract Cisplatin (CDDP) is commonly used to treat a multitude of tumors including sarcomas, ovarian and cervical cancers. Despite recent investigations allowed improve chemotherapy effectiveness, the molecular mechanisms underlying development CDDP resistance remain major goal in cancer research. Here, we show that mitochondrial morphology autophagy are altered different resistant cell lines. In osteosarcoma carcinoma, mitochondria fragmented closely juxtaposed endoplasmic reticulum; rates...
Immune checkpoint inhibitors cause side effects ranging from autoimmune endocrine disorders to severe cardiotoxicity. Periodic Fasting mimicking diet (FMD) cycles are emerging as promising enhancers of a wide range cancer therapies including immunotherapy. Here, either FMD alone or in combination with anti-OX40/anti-PD-L1 much more effective than immune delaying melanoma growth mice. also show trend for increased against lung model. As importantly, the cardiac fibrosis, necrosis and...
Postmenopausal women show the highest incidence of breast cancer in female population and are often affected by metabolic syndrome. Metabolic syndrome (MS) - characterized central adiposity, insulin resistance, low serum high-density lipoprotein cholesterol (HDL-C), high triglyceride blood pressure seems to be strictly correlated carcinogenesis. We enrolled 777 healthy with our nested case-control study evaluate association between MS cancer, analyzing anthropometric parameters (weight,...
Hyperglycemia, obesity and metabolic syndrome are negative prognostic factors in breast cancer patients. Immune checkpoint inhibitors (ICIs) have revolutionized treatment, achieving unprecedented efficacy multiple malignancies. However, ICIs associated with immune-related adverse events involving cardiotoxicity. We aimed to study if hyperglycemia could affect ipilimumab-induced anticancer enhance its Human cardiomyocytes estrogen-responsive triple-negative cells (MCF-7 MDA-MB-231 cell lines)...
Several strategies based on immune checkpoint inhibitors (ICIs) have been developed for cancer therapy, opening to advantages in outcomes. However, several ICI-induced side effects emerged these patients, especially a rare but clinically significant cardiotoxicity with high rate of mortality. We studied the cytotoxic and pro-inflammatory properties Ipilimumab Nivolumab, underlying pathways cytokine storm involved.Co-cultures human cardiomyocytes lymphocytes were exposed or Nivolumab; cell...
Immune checkpoint inhibitors (ICIs) have significantly changed the oncology clinic in recent years, improving survival expectations cancer patients. ICI therapy a broad spectrum of side effects from endocrinopathies to cardiovascular diseases. In this study, pro-inflammatory and pro-fibrotic short-term ICIs preclinical models were analyzed.Firstly, human vitro model, cardiomyocytes co-cultured with hPBMC exposed (with CTLA-4 or PD-1 blocking agents, at 200 nM) for 72 h. After treatment,...
The improvement in cancer therapy and the increasing number of long term survivors unearth issue cardiovascular side effects anticancer treatments. As a paradox survivors, delayed cardiotoxicity has emerged as significant problem. Two categories cardiotoxic antineoplastic drugs have been previously proposed: Type I cardiotoxicity, defined permanent is usually caused by anthracyclines; II considered reversible mainly related to monoclonal antibodies. antibodies associated trastuzumab,...
Renal cell carcinoma (RCC) represents the main renal tumors and are highly metastatic. Sunitinib, a recently-approved, multi-targeted Tyrosine Kinases Inhibitor (TKi), prolongs survival in patients with metastatic gastrointestinal stromal tumors, however dose related cardiotoxicity was well described. Polydatin (3,4',5-trihydroxystilbene-3-β-d-glucoside) is monocrystalline compound isolated from Polygonum cuspidatum consolidated anti-oxidant anti-inflammatory properties, no studies...
Background Immune checkpoint blockade in monotherapy or combinatorial regimens with chemotherapy radiotherapy have become an integral part of oncology recent years. Monoclonal antibodies against CTLA-4 PD-1 PDL-1 are the most studied ICIs randomized clinical trials, however, more recently, anti-LAG3 (Lymphocyte activation gene-3) antibody, Relatlimab, has been approved by FDA combination Nivolumab for metastatic melanoma therapy. Moreover, Atezolizumab is actually under study association...
Anthracycline-induced cardiomyopathies and sarcopenia are frequently seen in cancer patients, affecting their overall survival quality of life; therefore, new cardioprotective anti-sarcopenic strategies needed. Vericiguat is a oral guanylate cyclase activator that reduces heart failure hospitalizations or cardiovascular death. This study highlighted the potential properties vericiguat during anthracycline therapy. Human cardiomyocytes primary skeletal muscle cells were exposed to doxorubicin...